Guidelines Recommend Against Routine Pelvic Exams

Article

A new clinical practice guideline from the American College of Physicians recommends against conducting routine pelvic exams in average-risk, asymptomatic women.

The ACP recommends against routine pelvic exams in average-risk, asymptomatic women.

A new clinical practice guideline from the American College of Physicians (ACP) recommends against conducting routine pelvic exams in average-risk, asymptomatic women, finding they have no proven benefit and may lead to unnecessary pain, anxiety, and costs.

“Our primary conclusion is that no data support the use of routine pelvic examination (excluding cervical cytologic examination) for reducing the morbidity or mortality of any condition,” the authors state in an evidence report supporting the guideline published in the July 1 Annals of Internal Medicine. “Furthermore, limited evidence suggests that screening pelvic examinations may be associated with pain, discomfort, fear, anxiety, or embarrassment in about one-third of women and can lead to unnecessary, invasive, and potentially harmful diagnostic procedures.”

The recommendations, based on a systematic review of studies published since 1946, do not apply to Pap smears and visual inspection of the cervix during routine cervical cancer screening, which should be performed at intervals recommended by evidence-based guidelines for specific groups of women defined by age, presence of a cervix, and prior Pap test results. 

Pelvic exams used to screen for ovarian cancer have a positive predictive value of less than 4%, according to the report. In the Prostate, Lung, Colorectal, and Ovarian cancer screening trial that enrolled more than 78,000 women over 12 years, for example, the exam was dropped from the screening protocol after 5 years, because it did not detect any malignancies.

Other studies report that women who experience pain or discomfort during or before a pelvic exam are less likely to return for subsequent medical visits. The authors point to some data suggesting that fear of the exam may lead some younger women to delay or avoid obtaining oral contraceptives.

Pelvic exams also incur substantial costs to the health care system, the authors note. The United States spends an estimated $2.6 billion on preventive gynecologic exams and associated services annually, with about a third of that total for unnecessary cervical cancer screening in women under age 21.

The authors acknowledge that there may be indirect benefits of routine pelvic exams, such as encouraging women to access health care and receiving other gynecologic services and providing an opportunity to discuss sensitive issues, such as incontinence or sexual dysfunction. However, no studies have evaluated these possible benefits.

Despite a lack of evidence, many providers continue to perform routine exams as part of the well women annual visit, the authors note. In addition, the American College of Obstetricians and Gynecologists recommends annual exams, although the recommendation is based solely on expert opinion.

“Despite its widespread use in clinical practice, data supporting the use of the pelvic examination in asymptomatic women not at increased risk for gynecologic cancer are scant,” the authors conclude. “An important area for future research is the development and testing of strategies to reduce the high rate of inappropriate use of the pelvic examination.”

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Related Content